Trial Profile
A Phase 3 Randomized Trial of Concurrent Cisplatin and Radiotherapy With Or Without ONCOVEXGM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Sponsors BioVex
- 29 Jul 2011 Status changed from recruiting to discontinued.
- 10 Dec 2010 Status changed from not yet recruiting to recruiting.
- 02 Aug 2010 Status changed from planning to not yet recruiting, as reported in a BioVex media release.